ARTICLE SUMMARY:
Despite geopolitical challenges and fierce competition for capital, the medtech investment market has maintained the momentum from 2025 through 2026, according to PwC’s latest medtech deals outlook.
“Venture capital funding and IPO activity for medtech start-ups remain constrained, increasing pressure across the broader innovation ecosystem,” the consultancy concludes in its latest “outlook” paper on US medtech deals.
